Factors Impacting DFS in B-Cell Malignancy After CAR-T Administration – Journal of Clinical Pathways
Journal of Clinical Pathways |
Factors Impacting DFS in B-Cell Malignancy After CAR–T Administration
Journal of Clinical Pathways A recent study sought to determine the factors associated with durable remission after a complete response to CD19-targeting chimeric antigen receptor T cell (CAR-T) therapy in adult patients with B-cell acute lymphoblastic leukemia (B-ALL). The study … |
